Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and
gene-editing company utilizing artificial intelligence and
proprietary neural network platform with a therapeutic focus on
immuno-oncology, announces the filing of key European patents for
its chimeric PD-1 (chPD1) target.
- Kiromic chPD1 receptor targets PD-1 ligands expressed on many
different types of cancer cells, including ovarian, pancreatic,
prostate, colon, kidney, and breast cancer and melanoma.
- Kiromic chPD1-expressing T-cells engage with the PD-1 ligands
on the surface of the cancer cells and this interaction activates
the T-cells to directly kill the tumor cells.
- Kiromic chPD1 has shown in preclinical data to show a cytotoxic
response in 9 different in vivo models with 100% long-term PFS with
the induction of host memory responses.
- chPD1 will be used in the Company’s proprietary chimeric
antigen receptor therapy (CAR-T) platform using gamma-delta T-cells
(GD-T).
Kiromic’s deep understanding of the tumor micro environment
(TME) and the tumors' escape and masking mechanisms led to
development of a promising platform for chimeric antigen receptor
therapy (CAR-T).
We believe our allogenic CAR-T platform is significantly
stronger with chPD1 target licensed from Longwood University.
Prof. Amorette Barber of Longwood University will be heading up
our chPD1 program.
"We believe Prof. Barber's work will give Kiromic a significant
acceleration in the clinical development of its therapy platform
and an even more significant advantage over its competitors. We
believe this collaboration marks the beginning of an exciting
revolution in cell therapies," said Gianluca Rotino, Chief of
Strategy and Innovation Officer.
"chPD1 is an exciting and differentiated target for our
allogenic CAR-T solid tumors platform. We look forward to updating
you in the months ahead as we move closer to filing our first IND
with our chPD1 for ovarian cancer," said Maurizio
Chiriva-Internati, PhD, CEO of Kiromic Biopharma.
About PD-1 Check-point inhibition
PD-1 has always been a challenge for CAR-T development. PD-1 is
the brakes of the immune system, inhibiting immune cells from
killing tumor cells.
Traditional PD-1 inhibitors block the PD-1 receptor, “removing
the brakes” of T-cell activity. Conversely, Kiromic’s chPD1 not
only “removes the brakes” but also engages the PD-1 receptor to
“accelerate” T-cell activity.
About Kiromic chPD1 Mechanism of Action
Kiromic’s chPD1 receptor targets PD-1 ligands expressed on many
different types of cancer cells, including ovarian, pancreatic,
prostate, colon, kidney, and breast cancer and melanoma.
Chimeric PD-1-expressing T-cells engage with the PD-1 ligands on
the surface of the cancer cells and this interaction activates the
T-cells to directly kill the tumor cells. Chimeric PD-1 T-cells
also release cytokines to further initiate immune responses to
eradicate the tumor cells.
Through expression of the chPD1 receptor, the inhibitory signal
the T-cells would have received through engagement of the PD-1
ligands on tumor cells now acts as an activating signal and induces
destruction of tumors. A large variety of cancer types express PD-1
ligands thus the chPD1 T-cells could potentially be used to treat
many types of tumors.
About Dr. Amorette Barber (Longwood University)
Dr. Barber is an associate professor of biology and director of
the Office of Student Research. Dr. Barber is in her tenth year at
Longwood and serves as the President-Elect of the Virginia Academy
of Science.
Dr. Barber is a tumor immunologist. She is an expert in chimeric
antigen T-cells. Her research focuses on determining the role
costimulatory domains play in enhancing chimeric T-cell activity
and the creation and testing of the chPD1 receptor as a therapy for
multiple types of cancer.
Dr. Barber has had 26 publications in cellular signaling in the
following scientific journals: The Journal of Clinical
Investigation, Blood, Cancer Research, The Journal of Immunology,
and many others.
Link to her profile:
http://www.longwood.edu/directory/profile/barberarlongwoodedu/
Dr. Barber also serves on Kiromic’s Scientific Advisory
Board.
About Longwood University
Longwood has a robust research department with 7 post doctorates
conducting research in molecular biology, microbiology, genomics,
cancer biology, and immunology and publishing over 75 publications
in different scientific journals in the past 5 years.
Link to Longwood University: www.longwood.edu
About Kiromic
Kiromic BioPharma, Inc. is a preclinical stage biopharmaceutical
company which is focused on discovering, developing, and
commercializing novel immune-oncology applications through its
robust product pipeline. The pipeline development is leveraged
through the Company’s proprietary target discovery engine called
"DIAMOND." Kiromic's DIAMOND is big data science meeting target
identification, dramatically compressing man-years and billions of
drug development dollars to develop a live drug. The Company
maintains offices in Houston, Texas.
For more information, please visit the company’s website at
www.kiromic.com.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. We make such
forward-looking statements pursuant to the safe harbor provisions
of the U.S. Private Securities Litigation Reform Act, Section 21E
of the Securities Exchange Act of 1934, as amended, and other
federal securities laws. All statements other than statements of
historical facts are forward-looking statements. These statements
relate to future events or to our future financial performance and
involve known and unknown risks, uncertainties and other factors
that may cause our actual results, levels of activity, performance
or achievements to be materially different from any future results,
levels of activity, performance or achievements expressed or
implied by these forward-looking statements. Forward-looking
statements include, but are not limited to, statements about:
- our goals and strategies;
- our future business development, financial condition and
results of operations;
- expected changes in our revenue, costs or expenditures;
- growth of and competition trends in our industry;
- our expectations regarding demand for, and market acceptance
of, our products;
- our expectations regarding our relationships with investors,
institutional funding partners and other parties we collaborate
with;
- fluctuations in general economic and business conditions in the
markets in which we operate; including those fluctuations caused by
COVID-19; and
- relevant government policies and regulations relating to our
industry.
In some cases, you can identify forward-looking statements by
terms such as "may," "could," "will," "should," "would," "expect,"
"plan," "intend," "anticipate," "believe," "estimate," "predict,"
"potential," "project" or "continue" or the negative of these terms
or other comparable terminology. These statements are only
predictions. You should not place undue reliance on forward-looking
statements because they involve known and unknown risks,
uncertainties and other factors, which are, in some cases, beyond
our control and which could materially affect results. Factors that
may cause actual results to differ materially from current
expectations include, among other things, those listed under the
heading "Risk Factors" included in our Registration Statement on
Form S-1 (file no. 333-238153), originally filed with the
Securities and Exchange Commission (SEC) on May 11, 2020, as
amended, and elsewhere in this press release. If one or more of
these risks or uncertainties occur, or if our underlying
assumptions prove to be incorrect, actual events or results may
vary significantly from those implied or projected by the
forward-looking statements. No forward-looking statement is a
guarantee of future performance.
The forward-looking statements made in this press release relate
only to events or information as of the date on which the
statements are made in this press release. Except as expressly
required by the federal securities laws, there is no undertaking to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, changed
circumstances or any other reason. You are advised, however, to
review any further disclosures we make on related subjects in our
Forms 10-Q, 8-K and other reports filed with the SEC.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210104005863/en/
Tony Tontat Chief Financial Officer (844) 539 -
2873 ttontat@kiromic.com
Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart
From Sep 2023 to Sep 2024